Acadia Healthcare Company, Inc. (ACHC) 2019 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • As a reminder, this call is being recorded. Please proceed.

    提醒各位,本次電話會議正在錄音。請繼續。

  • Gretchen Hommrich - Director of IR

    Gretchen Hommrich - Director of IR

  • Good morning. And welcome to Acadia's Fourth Quarter 2019 Conference Call. To the extent any non-GAAP financial measure is discussed in today's call you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.

    早安。歡迎參加 Acadia 2019 年第四季電話法說會。若今日電話會議中討論任何非 GAAP 財務衡量指標,您亦可在我們網站的投資人連結中,查看昨日新聞稿,以取得該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。

  • This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2020 and beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements.

    本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義之前瞻性陳述,其中包括但不限於關於 Acadia 對 2020 年及其後預期之季度與年度財務表現的陳述。就此而言,本次電話會議中任何非歷史事實之陳述,均可能被視為前瞻性陳述。

  • Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's fourth quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.

    在不限制前述內容之前提下,「相信」、「預期」、「計畫」、「期望」及類似用語旨在識別前瞻性陳述。特此提醒您,這些陳述可能受到多項重要因素影響(其中包括但不限於)Acadia 向美國證券交易委員會提交之文件以及公司第四季新聞稿中所載之因素。因此,實際營運與結果可能與前瞻性陳述中討論之結果存在重大差異。公司不承擔公開更新任何前瞻性陳述之義務,無論係因新資訊、未來事件或其他原因所致。

  • At this time, for opening remarks, I would like to turn the conference call over to Chief Executive Officer, Debbie Osteen.

    現在進入開場致詞,我想將電話會議交給執行長 Debbie Osteen。

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • Good morning. And thank you for being with us today for our fourth quarter and year-end 2019 conference call. I'm here today with Chief Financial Officer, David Duckworth, and other members of our executive management team. David and I will provide some remarks about our financial and operating results for the fourth quarter and year. We will then open the line for your questions.

    早安。感謝各位今天與我們一同參加 2019 年第四季及全年年終電話會議。今天與我一同出席的有財務長 David Duckworth 以及我們執行管理團隊的其他成員。David 和我將就第四季及全年財務與營運結果提供一些說明。接著我們將開放線路供各位提問。

  • Our results for the fourth quarter were in line with our expectations. We achieved overall revenue growth of 4.9% over the fourth quarter of 2018, reflecting our continued focus on growth initiatives, both through service expansion at our existing facilities and additional bed capacity. On a same facility basis, overall revenue was up 4.5% in the fourth quarter of 2019 compared with 2018.

    我們第四季的結果符合我們的預期。相較於 2018 年第四季,我們整體營收成長 4.9%,反映我們持續聚焦於成長計畫,包括在既有機構擴展服務以及增加床位容量。以同店(same facility)基礎計算,2019 年第四季整體營收較 2018 年成長 4.5%。

  • Our U.S. facility showed solid improvement across key metrics. For the fourth quarter, U.S. same facility revenue increased 5.5%, with a 2.4% increase in patient days and a 3% increase in revenue per patient day compared with the prior year period. U.S. same facility EBITDA margin increased 30 basis points to 25% compared with 24.7% for the fourth quarter of 2018.

    我們美國機構在多項關鍵指標上呈現穩健改善。第四季,美國同店營收成長 5.5%;其中病患日(patient days)增加 2.4%,每病患日營收(revenue per patient day)較去年同期增加 3%。美國同店 EBITDA 利潤率提升 30 個基點至 25%,相較 2018 年第四季的 24.7%。

  • Regarding the specific facility issues that affected our results in the third quarter, we believe that we have addressed the issues with the action plans that have been implemented by our operations team during the fourth quarter. We are very pleased with the progress that has been made, which is in line with our expectations. David will provide additional details on the fourth quarter impact and 2020 expectations for these facilities.

    關於影響我們第三季結果的特定機構問題,我們相信在第四季由營運團隊所推動並已落實的行動方案,已經解決了相關問題。我們對已取得的進展感到非常滿意,且符合我們的預期。David 將就這些機構在第四季的影響以及 2020 年的預期提供更多細節。

  • During the fourth quarter, we added 171 beds, including 150 beds in the U.S. and 21 beds in the U.K. For the full year, we added 585 beds to existing and new facilities. Moving forward to 2020, we expect to add approximately 600 beds to existing and new facilities in the U.S. We are excited about these opportunities to expand capacity in our markets, which adds beds to 10 states across all service lines. 2020 presents an opportunity to add the highest number of beds to our U.S. facilities in the last 3 years.

    第四季我們新增 171 張床位,其中美國新增 150 張、英國新增 21 張。全年而言,我們在既有與新設機構合計新增 585 張床位。展望 2020 年,我們預期在美國既有與新設機構合計新增約 600 張床位。我們對於在各市場擴充容量的機會感到振奮,這將在所有服務線於 10 個州新增床位。2020 年將是過去 3 年來我們在美國機構新增床位數量最高的一年。

  • We also continue to work on our partnership strategy. We have a strong track record of partnering with health systems and hospitals across the country. We have 5 joint ventures operating and 3 currently in development. Our integration team has received increased interest from health systems who would like to partner with us. We now have a robust pipeline of approximately 30 projects.

    我們也持續推進合作夥伴策略。我們在全國與醫療體系及醫院合作方面擁有良好實績。目前有 5 個合資企業(JV)在營運,另有 3 個正在開發中。我們的整合團隊收到更多來自希望與我們合作之醫療體系的興趣。目前我們擁有約 30 個專案的強勁案源管線。

  • The market remains strong and the value proposition to our provider partners is very compelling. Acadia is collaborating with health system partners nationwide to improve integration of behavioral health care throughout their organization as they focus on population health initiatives and improving clinical outcomes for their patients. We look forward to opening a new joint venture hospital with Tower Health in Reading, Pennsylvania, planned for the second quarter and a new joint venture hospital with Ascension Saint Thomas planned for the fourth quarter. We also expect to open a de novo facility in Cincinnati, Ohio, planned for the fourth quarter of 2020. We are excited about these and other opportunities ahead for Acadia to meet the growing demands in the market, better serve the needs in the local community and advance our position as a leading operator of behavioral health care facilities.

    市場仍然強勁,我們對提供者合作夥伴的價值主張極具吸引力。Acadia 正與全國各地的醫療體系合作夥伴協作,在其聚焦族群健康(population health)計畫並改善病患臨床結果之際,提升其組織內行為健康照護的整合程度。我們期待於第二季在賓夕法尼亞州雷丁(Reading, Pennsylvania)與 Tower Health 開設新的合資醫院,並於第四季與 Ascension Saint Thomas 開設新的合資醫院。我們也預期於 2020 年第四季在俄亥俄州辛辛那提(Cincinnati, Ohio)開設一家新設(de novo)機構。我們對這些以及 Acadia 未來其他機會感到振奮,將可滿足市場日益成長的需求、更好地服務在地社區需求,並鞏固我們作為行為健康照護機構領先營運商的地位。

  • Additionally, we have seen new opportunities and pathways to grow in our CTC service line. We plan to open 6 CTC de novos in 2020 to expand our footprint into new markets that are underserved. As of January 1, Medicare expanded coverage to include opioid treatment programs. While it is too early to size the full benefit, we expect that this will drive volume growth by treating new patients and allowing improved coverage and access for dual-eligible patients. As you can see through our JV activity, new bed expansion and de novo activity, the growth opportunity in behavioral health services remains robust, and Acadia is well positioned to capitalize on these multiple pathways to grow revenue and profitability.

    此外,我們也在 CTC 服務線看到新的成長機會與途徑。我們計畫於 2020 年開設 6 家 CTC 新設(de novo)據點,以將版圖擴展至服務不足的新市場。自 1 月 1 日起,Medicare 擴大給付範圍,納入阿片類藥物治療計畫(opioid treatment programs)。雖然目前仍難以完整量化其效益,但我們預期這將透過治療新病患並改善雙重資格(dual-eligible)病患的給付與可近性,帶動量能成長。從我們的合資活動、新增床位擴張與新設(de novo)活動可見,行為健康服務的成長機會仍然強勁,而 Acadia 已具備良好定位,可把握多元途徑以提升營收與獲利能力。

  • Throughout the quarter, we have continued to make progress in achieving the savings generated through the operational initiatives outlined in the strategic review update we provided last May. We remain focused on implementing these initiatives to improve operational efficiencies throughout our operations. We believe we will achieve approximately $20 million in annualized cost savings by the end of 2020, which is in line with our original announcement in May of last year. As previously mentioned, most of the savings will be in procurement, which will impact supplies and other operating expenses.

    整個季度期間,我們持續在實現去年 5 月所提供之策略檢討更新中所列營運計畫所帶來的節省方面取得進展。我們仍專注於推動這些計畫,以提升整體營運效率。我們相信到 2020 年底可達成約 2,000 萬美元的年化成本節省,與我們去年 5 月原先公告一致。如先前所述,多數節省將來自採購,並將影響耗材及其他營運費用。

  • We have successfully completed a conversion of our contracted GPO in early February. Our new GPO will provide additional resources and closer alignment to drive the identified cost savings. As we continue to implement initiatives throughout the year, we expect a gradual ramp to the full run rate savings amount of $20 million by the end of the year. Because the facilities have done a fantastic job implementing the initial changes, we are very pleased with our progress to date and look forward to realizing the incremental benefits of our strategy while we continue to support our patients with the highest quality of care.

    我們已於 2 月初成功完成既有合約 GPO 的轉換。新的 GPO 將提供額外資源並更緊密對齊,以推動已識別的成本節省。隨著我們在全年持續推動各項計畫,我們預期節省將逐步爬升,至年底達到 2,000 萬美元的完整年化節省水準。由於各機構在落實初期變更方面表現出色,我們對目前的進展感到非常滿意,並期待在持續以最高品質照護支持病患的同時,實現策略所帶來的增量效益。

  • The performance of our U.K. facilities was in line with our expectations. For the fourth quarter, same facility revenue was up 2.7%, consisting of a 4.7% increase in revenue per patient day, driven by our rate increases from the NHS and local payers and higher reimbursement related to an increase in the acuity of our patients. The increase in revenue per patient day was partially offset by a 2% decrease in patient days, which is related to the retooling efforts we discussed on previous calls. Same facility EBITDA margin was 16.1%, consistent with our expectations.

    我們英國機構的表現符合我們的預期。第四季同店營收成長 2.7%,其中每病患日營收增加 4.7%,主要受 NHS 與地方付款方的費率調升,以及因病患病情嚴重度(acuity)提高而帶動較高給付所驅動。每病患日營收的增加,部分被病患日下降 2% 所抵銷,這與我們在先前電話會議中討論的重新調整(retooling)工作有關。同店 EBITDA 利潤率為 16.1%,符合我們的預期。

  • Operationally, the U.K. business continues to demonstrate stability. The team in the U.K. remains focused on operating the business as our process of assessing strategic alternatives continues. As we have previously discussed, the demand for our services in the U.K. has been consistent. Priory continues to receive referrals for the highest levels of acuity across all divisions and continuously reviews our services to ensure this market need is safely met.

    在營運層面,英國業務持續展現穩定性。在我們持續評估策略替代方案的過程中,英國團隊仍專注於業務營運。如我們先前所討論,英國對我們服務的需求一直保持一致。Priory 持續在所有事業部門收到最高急性程度個案的轉介,並持續檢視我們的服務,以確保能安全地滿足此市場需求。

  • At the end of the year, we had approximately 150 beds off-line for retooling. We have a detailed time line for each project, and we're working diligently to reopen the beds on schedule. We believe there is a real long-term benefit from retooling that will add value to our operations. With the beds that we've retooled, we have already seen good results and believe this will contribute to our future growth. We will continue to work with the NHS and other referral sources to identify areas in which we can help meet their demands and believe we are well positioned across our service lines.

    在年底時,我們約有 150 張病床因改造而暫停使用。我們為每個專案都制定了詳細的時間表,並正努力按計畫重新開放病床。我們相信改造將帶來真正的長期效益,並為我們的營運增值。就已完成改造的病床而言,我們已看到良好成果,並相信這將有助於我們未來的成長。我們將持續與 NHS 及其他轉介來源合作,找出我們可協助滿足其需求的領域,並相信我們在各項服務線上具備良好定位。

  • I would like to update you on our strategic review and potential sale of the U.K. business. As we announced last year, the Board has engaged a financial adviser to run a process to explore the sale of the entirety of our U.K. business. The formal process was launched in January 2020, following the U.K. elections and preliminary discussions with prospective buyers at the end of last year. Consistent with market practice for U.K. transactions of this nature and in conjunction with our advisers, we solicited and now have received initial nonbinding offers to acquire our U.K. business from multiple bidders. We are currently in the second phase of the sale process, during which interested bidders will receive proposed transaction documents and complete their confirmatory due diligence. We expect to complete the sale of our U.K. business in the second quarter or early in the third quarter of 2020 if, as a result of our sales process, we receive a final firm offer that our Board determines maximizes value for our shareholders.

    我想向各位更新我們的策略檢討以及英國業務的潛在出售進展。如我們去年所宣布,董事會已聘請財務顧問主導流程,以探索出售我們英國業務整體的可能性。在英國大選之後,並於去年底與潛在買方進行初步討論後,正式流程於 2020 年 1 月啟動。依照此類英國交易的市場慣例,並在顧問協助下,我們已徵詢且目前已收到多位競標者提出的初步非約束性收購要約,以收購我們的英國業務。我們目前正處於出售流程的第二階段,在此期間,有意競標者將收到擬議交易文件並完成其確認性盡職調查。若在本次出售流程下,我們收到董事會認定可為股東創造最大價值的最終具約束力要約,我們預期將於 2020 年第二季或第三季初完成英國業務的出售。

  • Lastly, before I turn the call over to David, I'd like to set the stage for 2020. We will continue to focus on quality in everything we do, whether it is maintaining exceptional standards and patient care across our network, investing in new beds or acquiring hospitals to serve the critical needs in our society or aligning ourselves with the premier joint venture partners around the U.S. We are pursuing a purposeful and best-in-class growth trajectory. We will continue to deleverage the company while making prudent investments based on a disciplined return on capital allocation framework. As we continue to grow our 4 lines of business, you will see the synergies, complementary investments and corresponding operating leverage we can achieve through this approach. We believe Acadia is in the ideal position to meet the tremendous market need that exists.

    最後,在我把電話會議交給 David 之前,我想先為 2020 年做個鋪陳。我們將持續在所有工作上聚焦品質,不論是維持我們網絡中卓越的標準與病患照護、投資新增病床或收購醫院以服務社會的關鍵需求,或是在全美與頂尖合資夥伴結盟。我們正追求有目的、同級最佳的成長軌跡。我們將在遵循嚴謹的資本配置報酬框架下,一方面持續降低槓桿,一方面進行審慎投資。隨著我們持續擴展四大業務線,各位將看到透過此方法可達成的協同效應、互補性投資以及相應的營運槓桿。我們相信 Acadia 處於理想位置,足以滿足市場上龐大的需求。

  • Now I will turn the call over to David Duckworth to discuss our financial results and guidance in more detail.

    現在我將把電話會議交給 David Duckworth,請他更詳細說明我們的財務結果與財測指引。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Thanks, Debbie, and good morning. Revenue for the fourth quarter was $780.2 million compared with $743.5 million for the fourth quarter of 2018. Our consolidated revenue growth of 4.9% was affected by revenue generated by closed facilities in the prior year. The closed facilities had a $9.4 million -- had $9.4 million of revenue in the fourth quarter of 2018, which represents a 1.3% impact on revenue growth. Consolidated revenue growth adjusted for these facility closures was 6.2%.

    謝謝 Debbie,大家早安。第四季營收為 7.802 億美元,對比 2018 年第四季的 7.435 億美元。我們合併營收成長 4.9% 受到前一年已關閉設施所產生營收的影響。已關閉設施在 2018 年第四季貢獻 940 萬美元營收,對營收成長造成 1.3% 的影響。若就這些設施關閉因素調整後,合併營收成長為 6.2%。

  • As a reminder, our fourth quarter 2018 U.S. revenue was impacted by an accounts receivable adjustment of approximately $8 million. Adjusting our U.S. same facility stats for this adjustment as well as the impact from the specific facilities we highlighted in the third quarter, fourth quarter 2019 U.S. same facility revenue growth was 6.6%. Patient day growth was 4.4%. Revenue per patient day growth was 2.2% and EBITDA margins increased 40 basis points as compared to the prior period. The company's consolidated adjusted EBITDA for the fourth quarter of 2019 was $144.4 million or 18.5% of revenue. Adjusted income attributable to Acadia stockholders for the fourth quarter of 2019 was $45 million or $0.51 per diluted share, excluding transaction-related expenses of $11.8 million, a $54.4 million loss on impairment and an income tax effect of adjustments to income of $9.9 million based on a tax rate of 18.1%. The loss on impairment relates to property values at facilities that were closed during 2019.

    提醒各位,我們 2018 年第四季美國營收受到約 800 萬美元應收帳款調整的影響。在將此調整以及我們於第三季所強調之特定設施的影響一併納入調整後,2019 年第四季美國同店營收成長為 6.6%。病患日數成長為 4.4%。每病患日營收成長為 2.2%,且 EBITDA 利潤率較前期提升 40 個基點。公司 2019 年第四季合併調整後 EBITDA 為 1.444 億美元,約占營收 18.5%。2019 年第四季歸屬於 Acadia 股東的調整後淨利為 4,500 萬美元,或稀釋後每股 0.51 美元;此數字不包含 1,180 萬美元交易相關費用、5,440 萬美元減損損失,以及按 18.1% 稅率計算、對所得調整所產生的 990 萬美元所得稅影響。該減損損失與 2019 年關閉之設施的資產價值相關。

  • Turning to our financial guidance and as noted in our press release, we are providing guidance for the full year 2020 as follows: revenue in a range of $3.28 billion to $3.34 billion; adjusted EBITDA in a range of $610 million to $630 million; adjusted earnings per diluted share in a range of $2.20 to $2.40; depreciation and amortization expense in a range of $175 million to $180 million; interest expense in a range of $172 million to $177 million; total diluted shares outstanding of approximately 88.1 million shares; operating cash flows in a range of $375 million to $420 million (sic) [$410 million]; total capital expenditures in a range of $330 million to $350 million, which includes maintenance CapEx of approximately $90 million. Our guidance also assumes an exchange rate of $1.30 per British pound sterling and a tax rate of approximately 17%.

    接著談我們的財測指引,如新聞稿所述,我們對 2020 全年提供以下指引:營收介於 32.8 億至 33.4 億美元;調整後 EBITDA 介於 6.10 億至 6.30 億美元;稀釋後每股調整後盈餘介於 2.20 至 2.40 美元;折舊與攤銷費用介於 1.75 億至 1.80 億美元;利息費用介於 1.72 億至 1.77 億美元;稀釋後流通在外股數約 8,810 萬股;營運現金流介於 3.75 億至 4.20 億美元(原文如此)[$4.10 億];資本支出總額介於 3.30 億至 3.50 億美元,其中包含約 9,000 萬美元的維護性資本支出。我們的指引亦假設英鎊兌美元匯率為 1.30,稅率約為 17%。

  • Our guidance for the first quarter of 2020 is as follows: revenue in a range of $795 million to $805 million; adjusted EBITDA in a range of $133 million to $137 million; and adjusted earnings per diluted share in a range of $0.37 to $0.42. This guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses.

    我們對 2020 年第一季的指引如下:營收介於 7.95 億至 8.05 億美元;調整後 EBITDA 介於 1.33 億至 1.37 億美元;稀釋後每股調整後盈餘介於 0.37 至 0.42 美元。此指引不包含任何未來併購、資產處分或交易相關費用的影響。

  • Due to the process relating to our U.K. business, we are providing the following annual guidance for that segment for 2020: revenue in a range of $1.16 billion to $1.19 billion; adjusted EBITDA in a range of $180 million to $190 million; and depreciation expense related to our U.K. business in a range of $78 million to $80 million.

    由於與我們英國業務相關的流程,我們對該事業部門提供 2020 年以下年度指引:營收介於 11.6 億至 11.9 億美元;調整後 EBITDA 介於 1.80 億至 1.90 億美元;以及與英國業務相關的折舊費用介於 7,800 萬至 8,000 萬美元。

  • As we look to 2020, there are several items that we would like to highlight regarding the timing of factors that impact our guidance. First, we continue to see progress at the specific facilities we highlighted in the third quarter of 2019. The action plans at these facilities have been implemented. We're seeing these facilities ramp up and expect improvement will continue through the first and second quarter. Second, as Debbie mentioned, we expect to see an ongoing contribution from the operational improvement initiatives throughout the year, which we expect to achieve a run rate of $20 million by the end of the year. Third, we expect bed additions to continue to drive strong growth throughout the year. We have added 585 beds in 2019 and expect to bring approximately 600 beds online in the U.S. in 2020.

    展望 2020 年,我們想就影響指引的因素時點,強調幾個事項。第一,我們持續看到 2019 年第三季所提及之特定設施的進展。這些設施的行動計畫已經落實。我們看到這些設施逐步提升產能,並預期改善將延續至第一季與第二季。第二,如 Debbie 所提到,我們預期全年營運改善計畫將持續帶來貢獻,並預期在年底達到 2,000 萬美元的運行率。第三,我們預期新增病床將持續推動全年強勁成長。我們在 2019 年新增 585 張病床,並預期在 2020 年於美國約有 600 張病床投入營運。

  • As a result of these factors, we expect to achieve revenue growth in the 5% to 7% range throughout 2020 for our U.S. operations. Additionally, in the second half of the year, we expect to achieve our goal of revenue growth at the high end of that range and EBITDA margin improvement for our U.S. operations.

    由於這些因素,我們預期2020年我們在美國業務的營收成長將落在5%至7%的區間。此外,在下半年,我們預期可達成美國業務營收成長位於該區間高端的目標,並改善EBITDA利潤率。

  • This concludes our prepared remarks this morning. I will now ask Lisa to open the floor for your questions.

    以上為我們今天上午的預先準備發言。接下來我將請Lisa開放現場進行提問。

  • Operator

    Operator

  • (Operator Instructions) We'll take our first question from A.J. Rice with Crédit Suisse.

    (接線員指示) 我們的第一個問題來自瑞士信貸(Crédit Suisse)的A.J. Rice。

  • Albert J. William Rice - Research Analyst

    Albert J. William Rice - Research Analyst

  • Just maybe looking at the U.K., I think you're putting -- is the slight moderation in growth in the fourth quarter revenue and EBITDA versus what you'd seen earlier in the year, it sounds like that's mostly just retooling beds to get ready to take higher acuity patients. But we also do have the political backdrop going on and the move ahead with Brexit and so forth. Is it still your view that, that's not having any impact on the business or the way NHS is relating to either staffing needs across the country or reimbursement or patient fund?

    先看英國這邊,我想你們提到——第四季營收與EBITDA的成長相較於年初所見略有放緩,聽起來主要是因為在重新調整床位,以便接收病情更嚴重(更高照護強度)的病患。但同時也有政治背景因素,包括推進脫歐等。你們是否仍認為這些因素對業務沒有任何影響,或對NHS在全國人力配置需求、給付/報銷或病患基金方面的作法沒有影響?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • A.J., I've talked with the team in the U.K., and they don't see any significant impact from Brexit. I think that historically, they really employ very few people from Europe, I think less than 5% of their workforce. But they don't see that being an impact. I think as far as the election and just the political climate, there is a focus on mental health throughout the U.K. I think that there may be more funding through NHS, but there's not going to be capital necessarily for extra beds. So we think there's actually going to be more opportunities for independent providers. And there are provider collaboratives that are going to be in place and, hence, there's been a lot of discussion. They actually become effective in the spring. We're very involved with that, and we think that's going to open new opportunities regionally for us. So we don't see an impact from the Brexit.

    A.J.,我已和英國團隊談過,他們沒有看到脫歐帶來任何顯著影響。我認為從歷史上看,他們雇用的歐洲員工非常少,應該不到其人力的5%。但他們不認為這會造成影響。至於選舉以及整體政治氛圍,英國各地都在關注心理健康議題。我認為NHS可能會提供更多資金,但不一定會有資本支出用於增加額外床位。因此我們認為,獨立提供者其實會有更多機會。而且將會建立提供者協作體系,因此也有很多討論。它們會在春季正式生效。我們非常積極參與其中,並認為這將在區域層面為我們帶來新的機會。所以我們不認為脫歐會造成影響。

  • And also, we don't see really changes in the labor market. There are talks about doing more from an NHS perspective to provide more training and money to -- for education for nurses and others, but we will be a recipient of that if that happens.

    另外,我們也沒有看到勞動市場出現明顯變化。目前有一些討論,從NHS角度將投入更多資源,提供更多訓練與資金——用於護理師及其他人員的教育;若真的發生,我們也會是受益者。

  • Albert J. William Rice - Research Analyst

    Albert J. William Rice - Research Analyst

  • Okay. And then maybe my follow-up would be around the discussion around partnerships with health systems. That seems like it's going to become an increasing avenue for growth. Can you just tell us now that, that's sort of settled out last year or 2, anything about the terms of the deals? Is every deal its own thing? Or is there own situation? Or is there interesting aspects to the way terms are being done? Are most of these situations competitive? Are they coming through brokers? Or these things at your network, you just are making contact with systems and really pretty much working with them exclusively?

    好的。那我接著想追問的是,關於與醫療體系合作夥伴關係的討論。這似乎將成為愈來愈重要的成長途徑。可否談談,現在在過去一兩年趨於穩定之後,交易條款方面有什麼可以分享的?每一筆交易都是各自不同嗎?還是有固定的模式?或在條款設計上有什麼有趣的做法?這些情況大多是競爭性流程嗎?會透過仲介/投行嗎?還是多半是透過你們的網絡,你們直接與醫療體系接觸,基本上以獨家方式合作?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • I'd probably answer that, A.J., to say all of the above. I think that there are some processes that are competitive. There are some systems that have taken the position they want to hire bankers to represent them and look at who is out there to partner with them. We also have several that have not done a competitive process, have reached out to us exclusively. And I think that's based really on our track record. Most of the systems will do a back check of how we are doing with our partnerships. And when they do that, we have excellent recommendations from the partners that we currently have our existing relationships with.

    A.J.,我大概會回答:以上皆是。我認為有些流程是競爭性的。有些醫療體系採取的立場是,他們希望聘請投資銀行代表他們,看看市場上有哪些對象可以合作。我們也有好幾個案例並未進行競爭性流程,而是獨家與我們接洽。我認為這主要是基於我們的過往績效。多數醫療體系會對我們在合作案中的表現做背景查核。而當他們這麼做時,我們從目前既有合作夥伴那裡得到非常好的推薦與評價。

  • But I also think that it's a growing area. And I think, as I said in my remarks, we see actually more systems reaching out to us because I think they are seeing that they need to have mental health expertise as they look at how to serve their patients, population health and other areas. Each one is really different. And I think that we do have a template that we try and look at for deal terms. But we also want to be responsive to our partners. We want to listen to what they feel is appropriate, and we usually come to terms so that it's really positive for both of us.

    但我也認為這是一個正在成長的領域。而且正如我在發言中提到的,我們確實看到更多醫療體系主動與我們接觸,因為我想他們在思考如何服務其病患、族群健康(population health)及其他領域時,意識到需要心理健康方面的專業。每一個案子其實都不一樣。我們確實有一個範本,會用來檢視交易條款。但我們也希望能回應合作夥伴的需求。我們會傾聽他們認為合適的方式,通常也能達成對雙方都非常正面的條件。

  • Operator

    Operator

  • We'll take our next question from Brian Tanquilut with Jefferies.

    接下來我們的問題來自Jefferies的Brian Tanquilut。

  • Jason Michael Plagman - VP

    Jason Michael Plagman - VP

  • It's Jason Plagman on for Brian. Thanks for the update on the U.K. sale process. So looking forward, any thoughts on potential deployment of the proceeds you'd receive from a transaction? And then thoughts on potential capital structure, debt leverage, things like that, after a potential transaction.

    我是代替Brian提問的Jason Plagman。謝謝你們更新英國出售流程的進展。展望未來,對於交易可能取得的款項,你們是否有任何資金運用的想法?另外,若交易完成後,對於資本結構、負債槓桿等方面有何看法?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Jason, this is David. We don't have specifics to share with you at this time. We do intend to deleverage the company and have a capital structure that allows us to pursue the growth and the different opportunities that we believe we have. The initial intent is absolutely to deleverage the company, and we will share more specifics on what that looks like immediately and in the long term for our capital structure as the process continues.

    Jason,我是David。目前我們沒有具體細節可以與你分享。我們確實打算降低公司的槓桿,並建立一個能讓我們追求成長與我們認為存在的各種機會的資本結構。初步意圖絕對是先去槓桿化;隨著流程推進,我們會分享更多關於資本結構在短期與長期的具體樣貌。

  • Jason Michael Plagman - VP

    Jason Michael Plagman - VP

  • Okay, fair enough. And then my follow-up, it seems like the de novo performance improved in Q4. Can you talk about the outlook for those facilities in 2020? And then what you've baked into your guidance for 2020 as far as EBITDA impact from the new de novos you have plan to open in 2020?

    好的,了解。那我的追問是,看起來第四季de novo(新設)據點的表現有所改善。你能談談2020年這些機構的展望嗎?另外,就你們2020年指引而言,對於2020年計畫開設的新de novo據點,EBITDA影響你們已納入多少?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Sure. We did talk about having 2 new facilities that opened in the first quarter of 2019 and some of the start-up losses relating to those facilities throughout the year. We were very pleased that both of those facilities achieved breakeven in the fourth quarter, that is within a year of opening. That is the goal that we generally have for our new facilities. And both of those facilities, after getting off to a slow start, did achieve that goal in the fourth quarter.

    當然可以。我們確實提到,2019年第一季有2家新機構開業,且全年都有與這些機構相關的開辦期虧損。我們很高興這兩家機構在第四季都達到損益兩平,也就是在開業一年內達標。這通常是我們對新機構設定的目標。而這兩家機構在起步較慢之後,確實在第四季達成了該目標。

  • For the new facilities that we mentioned earlier for 2020, we do have about $5 million of start-up cost in our 2020 guidance relating to those facilities. Those open throughout the year. So unlike 2019 where we had 2 at the same time, we have more of a phased approach for the de novos that we see coming online in 2020, but the start-up losses for those will be $5 million as a group.

    至於我們先前提到的2020年新機構,我們在2020年指引中已納入約500萬美元的開辦成本,與這些機構相關。它們會在全年不同時間點開業。因此不同於2019年同時開出2家,2020年我們看到的de novo上線會採取較分階段的方式;但這些新設據點合計的開辦期虧損將為500萬美元。

  • Operator

    Operator

  • We'll take our next question from Ralph Giacobbe with Citi.

    接下來我們的問題來自花旗(Citi)的Ralph Giacobbe。

  • Ralph Giacobbe - Director

    Ralph Giacobbe - Director

  • Just want to go to the guidance, specifically the revenue guidance for 6.5% revenue growth. 2019, obviously, a slower year and you still have the U.K. challenges and under a sales process. So I guess just a comfort on that magnitude of growth. And maybe if you can give us sort of the underlying growth expectations for the U.S. and the U.K.

    我想回到指引,特別是6.5%營收成長的營收指引。2019年顯然是較慢的一年,而且你們仍面臨英國的挑戰並處於出售流程中。所以我想確認一下,對於這樣的成長幅度你們的把握/信心來源是什麼。另外,如果可以的話,能否提供美國與英國各自的基礎成長預期?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Sure. This is David. We do have a strong revenue growth outlook in both the U.S. and the U.K. We are expecting for the U.S. 5% to 7% revenue growth throughout the year. And we see that being at the high end of the range in the second half of the year, with the primary factors driving that being the bed additions being a strong number as well as the facilities that we highlighted in the third quarter improving throughout the year.

    當然。我是 David。我們在美國與英國兩個市場的營收成長展望都相當強勁。我們預期美國全年營收成長為 5% 至 7%。而我們認為下半年會落在區間高端,主要驅動因素包括新增床位數表現強勁,以及我們在第三季提到的那些機構在全年持續改善。

  • In the U.K., we also have a strong revenue growth outlook, and that primarily relates to the retooling. We now have, for the 150 beds that are currently off-line, a detailed time line as to when those beds come back online. And we see that starting in the first quarter and continuing throughout the year. And so the volume growth that we see in the U.K. and the project time lines that we have supporting the visibility that we now have around the retooling is the key driver of the revenue growth in the U.K. Our pricing outlook in both markets is between 2% and 3%. So in addition to the volume, we do expect an ongoing stability and strong pricing in the 2% to 3% range.

    在英國,我們同樣有強勁的營收成長展望,而這主要與改造(retooling)有關。目前對於現正離線的 150 張床位,我們已經有一份詳細的時間表,說明這些床位何時會重新上線。我們看到這將從第一季開始並持續到全年。因此,我們在英國看到的量能成長,以及我們所掌握的專案時程,支撐了我們如今對改造進度的可視性,這是推動英國營收成長的關鍵因素。我們在兩個市場的定價展望介於 2% 到 3%。所以除了量能之外,我們也預期 2% 到 3% 區間內的價格將持續穩定且強勁。

  • Ralph Giacobbe - Director

    Ralph Giacobbe - Director

  • Okay. That's helpful. And then just to follow-up. Maybe I missed it. Can you give us what the U.K. volume growth would have been ex retooling? And is that sort of the bridge? Because I think given the guidance you gave just on the U.K. of EBITDA of $180 million to $190 million, I think that implies, at the midpoint, growth of about 11% EBITDA growth. So can you just help bridge that? I mean that's a pretty sizable jump kind of year-over-year to what we saw in '19.

    好的。這很有幫助。接著再追問一下。也許我漏聽了。你們能否提供英國在排除改造影響(ex retooling)下的量能成長會是多少?以及這是否就是那個銜接(bridge)?因為我認為,依你們剛給的英國 EBITDA 指引 1.8 億到 1.9 億美元來看,中位數大概意味著 EBITDA 成長約 11%。所以能否協助我們把這之間的關係串起來?我的意思是,這相較於我們在 2019 年看到的水準,年對年是相當大的一個跳升。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Sure. In the U.K., there is about a 2% impact from the retooling beds. The revenue per day performance has been strong on increased pricing as well as improved acuity and service mix. But there is the volume impact from the beds that were closed for retooling. So as those beds come back online, we think there's 2% volume growth just from that, with other volume growth relating to an overall improvement in the U.K. occupancy. And so mid-single-digit U.K. revenue growth is supported by the retooling beds coming back online; overall, other opportunities we have in the occupancy as well as the pricing that we mentioned.

    當然。在英國,改造床位約帶來 2% 的影響。每床日營收表現強勁,來自於價格上調以及病患嚴重度(acuity)與服務組合的改善。但確實存在因改造而關閉床位所造成的量能影響。因此,當這些床位重新上線時,我們認為僅就此因素就會帶來 2% 的量能成長,其他量能成長則與英國整體入住率的改善有關。因此,英國中個位數的營收成長,係由改造床位重新上線所支撐;整體而言,也包含我們在入住率方面的其他機會,以及我們提到的定價。

  • So the U.K. revenue growth is in that 4% to 6%. If you look at it on a constant currency basis, there's a little bit of contribution from the foreign currency. So I'm not sure if you're seeing that in your numbers. But on a same constant currency basis, it's a mid-single-digit expectation for the U.K.

    所以英國的營收成長大約在 4% 到 6%。若以固定匯率(constant currency)基礎來看,外匯會有一點貢獻。所以我不確定你是否在你的數字裡看到這一點。但在相同的固定匯率基礎下,對英國的預期是中個位數。

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • I'll just add that as we have been opening the retooled beds, that the team in the U.K. has had a lot of success working with commissioners to obtain block contracts. And what that does is it assures us of reimbursement for all of the beds we're reopening. And it gives us the ability to ramp back up on our staffing and get the beds back open, but through a block contract that assures payment. And we have over 30 of those presently. And as we do reopen and we get to a point where we finish construction, that's when the negotiation starts with our commissioners. And I think that protects us a little bit from reopening the beds and having to ramp back up because we have taken that down, obviously, for construction. So they've done a good job with that. And we expect more of those with the retooled beds that open during 2020.

    我再補充一點:隨著我們逐步開放完成改造的床位,英國團隊在與委託方(commissioners)合作以取得包量合約(block contracts)方面非常成功。這樣做能確保我們對所有重新開放的床位都能獲得給付。也讓我們能夠把人力配置逐步拉升、讓床位重新開放,同時透過包量合約來確保付款。目前我們已有超過 30 份這類合約。而當我們重新開放、並且工程完工到一定階段時,就會開始與委託方進行協商。我認為這在某種程度上保護了我們,避免在重新開床、需要把人力拉升時承擔過多風險,因為在施工期間我們顯然已經把規模降下來了。所以他們在這方面做得很好。而我們預期在 2020 年隨著更多改造床位開放,這類合約也會增加。

  • Operator

    Operator

  • We'll take our next question from Kevin Fischbeck with Bank of America.

    下一題我們請美國銀行(Bank of America)的 Kevin Fischbeck。

  • Joanna Sylvia Gajuk - VP

    Joanna Sylvia Gajuk - VP

  • This is actually Joanna Gajuk filling in for Kevin today. So first, I guess, just want to clarify -- or I guess also get additional color on the comment around the U.K. sale process. So you said you expect to complete this transaction, I guess, at the end of Q2 into Q3. So does it mean that you think it's going to be closed? Or you're going to have a final decision announced by that time?

    今天其實是由 Joanna Gajuk 代替 Kevin 提問。首先,我想先釐清——或也想請你們就英國出售流程的評論再補充一些細節。你們說預期在第二季末到第三季完成這筆交易。這是否表示你們認為交易會在那個時間點完成交割?還是說你們會在那個時間點宣布最終決定?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • Well, we're in the second phase, Joanna, of our process. And when we talk about the second quarter, early into third, we're talking about completing the sale and actually having that finished. Now that is providing that we do have, as I said in my remarks, a firm and final bid that we determine maximizes value. But if we do have those circumstances, we expect to close either second quarter or early third quarter.

    Joanna,我們目前正處於流程的第二階段。當我們談到第二季、第三季初時,我們指的是完成出售並且實際把交易完成。當然,前提是如我在發言中所說,我們確實收到我們認定能使價值最大化的具約束力且最終的出價。若具備這些條件,我們預期會在第二季或第三季初完成交割。

  • Joanna Sylvia Gajuk - VP

    Joanna Sylvia Gajuk - VP

  • Okay. Great. And the other piece, so I appreciate the comment that you're not commenting on specifics in terms of the use of proceeds. But just philosophically or, I guess, longer term, when you talk about trying to delever. So can you give us a frame, I guess, how you think about the optimal lever for the remaining U.S. business? Are you thinking more 4x? Or is it a different number in terms of debt-to-EBITDA kind of target for the business?

    好的。了解。另外一點,我理解你們不會就資金用途(use of proceeds)的細節做評論。但從理念上或較長期的角度,當你們談到要去槓桿(delever)時,能否給我們一個框架,說明你們如何看待剩餘美國業務的最佳槓桿水準?你們是偏向 4 倍?或是以負債對 EBITDA 的目標來看,會是不同的數字?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes. I mean. We're confirming that we are targeting a leverage that is lower than where we are today. We will provide more specifics and a range once we complete the deal.

    是的。我的意思是。我們確認我們的目標是把槓桿降到低於目前水準。在交易完成後,我們會提供更具體的細節與區間。

  • Joanna Sylvia Gajuk - VP

    Joanna Sylvia Gajuk - VP

  • Okay. Great. And if I also can squeeze in a question on the guidance. So you now, you are talking about the specific segment, the U.K. growth seems to be implying -- or the guidance for the U.K. business seems to be implying pretty decent growth. But when we put the numbers on the paper, it seems like for the U.S., it's kind of surprisingly low. So is there a missing piece in terms of the unallocated corporate overhead that we should be also considering here in terms of just trying to get the implied U.S. numbers? Because we're getting a very low single-digit growth rate. So I don't think that, that will be what the guidance should be implying. Because you're talking about a much stronger revenue growth on a same-store basis. So can you just frame to us how you think about the U.S. growth outlook for the EBITDA in 2020? Or maybe also throw it in there, kind of long term in terms of how you think about that business.

    好的。了解。如果我也能再塞一個關於指引的問題。你們現在談到分部的具體情況,英國的成長看起來——或英國業務的指引看起來——意味著相當不錯的成長。但當我們把數字寫在紙上時,美國的部分看起來卻意外地偏低。所以在推算美國隱含數字時,是否有一個我們漏掉的部分,例如未分攤的公司層級費用(unallocated corporate overhead)也需要納入考量?因為我們算出來是非常低的個位數成長率。所以我不認為那會是指引所應該隱含的結果。因為你們談到同店基礎下更強勁的營收成長。所以你們能否為我們說明一下,你們如何看待 2020 年美國 EBITDA 的成長展望?或者也可以順帶談談更長期你們如何看待那項業務。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Sure, Joanna. And we did provide the guidance around the margin throughout the year with improvement happening throughout the year. And really, in the second half of the year, getting to a margin improvement on a year-over-year basis. The EBITDA, if you just look at our U.S. facilities without the corporate overhead, it is in a strong mid- to upper single-digit range. The timing is just part of that, as we mentioned.

    當然可以,Joanna。而且我們在全年都提供了關於利潤率的指引,並且利潤率在全年持續改善。實際上,在下半年,我們在年對年基礎上實現了利潤率改善。若僅看我們美國的設施、不含公司總部的管理費用,EBITDA 處於強勁的中到高個位數百分比區間。如同我們提到的,時點因素只是其中一部分。

  • If you include the corporate office costs, let me just provide the detail around that because it sounds like that is something to clarify. We did finish 2019 with about $84 million of corporate overhead in the U.S. That supports our U.S. facilities. We don't have overhead in that number relating to our U.K. operations. We do see that growing and the expectation for next year is in a range of $95 million to $98 million. The reason for that really is items in the 2019 number that just caused that to be lower than what we target in the normal year. Specifically, our bonus accruals are resetting in the 2020 guidance to more the targeted number, so that is the primary reason for our corporate office projection going from $84 million to around the $95 million to $98 million range.

    如果把公司總部成本也納入,我讓我就此提供一些細節,因為聽起來這是需要釐清的部分。我們在2019年結束時,美國的公司管理費用約為8,400萬美元,用以支援我們的美國設施。這個數字不包含與我們英國營運相關的管理費用。我們確實看到該費用成長,且對明年的預期區間為9,500萬至9,800萬美元。其原因主要是2019年的數字中有一些項目,使其低於我們在正常年度所設定的目標水準。具體而言,我們的獎金提列在2020年指引中會重設回較接近目標的水準,因此這是公司總部費用預估從8,400萬美元提高到約9,500萬至9,800萬美元區間的主要原因。

  • Operator

    Operator

  • We're taking our next question from Pito Chickering with Deutsche Bank.

    我們的下一個問題來自德意志銀行(Deutsche Bank)的 Pito Chickering。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • First one, on bed retooling. Can you just quantify the number of beds that were retooled and open during '19? And that's in addition to the 150 that are closed at the end of the year.

    第一個問題,關於病床重新配置(retooling)。你們能否量化一下在2019年期間重新配置並開放的病床數量?另外,這是除了年底關閉的150張病床之外的數量。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Pito, we did have

    Pito,我們確實有

  • (technical difficulty)

    (技術問題)

  • Gone through the

    經歷了

  • (technical difficulty)

    (技術問題)

  • '19, and we mentioned having 150 beds at the end of the year that we'll be reopening in 2020.

    在2019年,我們提到年底有150張病床,將在2020年重新開放。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Okay. And then during, I guess, to A.J.'s question, you talked about provider collaborations, which I believe starts in April. Do you think that led to -- do that lead to any new bed retoolings throughout the year? Or do you think that sort of the 150 and then have those come online, we won't see any additional bed retoolings during 2020?

    好的。那接著,回到我想是 A.J. 的問題,你提到與醫療服務提供者的合作,我理解是從4月開始。你認為這會不會導致全年出現——帶來任何新的病床重新配置?或者你認為就是那150張,等它們重新上線後,2020年就不會再看到任何額外的病床重新配置?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • The team believes that we're really at, I think, the peak of the retooling. I don't think that they expect to have a substantial number of beds like we've seen in 2019. We're always going to look for opportunity. If we think a bed could be providing a higher level of service, if we're asked by our customers. But there aren't any plans to do any more in a -- more of a material way around the retooling for this year.

    團隊認為我們確實已經處於重新配置的高峰期。我不認為他們預期會出現像2019年那樣大量的病床。我們一向會尋找機會。如果我們認為某張病床可以提供更高層級的服務,或是客戶提出需求。但今年在病床重新配置方面,沒有任何以更重大規模進行的計畫。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Okay. Great. And then the last question, beginning in the U.S., have you seen any impact from niche competitors in autism or eating disorders in your markets?

    好的。很棒。最後一個問題,先從美國開始,你們在市場上是否看到來自自閉症或飲食失調等利基競爭者的任何影響?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • We really haven't. There are competitors in both of those areas. We don't do -- we do provide some autism services but not to any great extent. We have several eating disorder specialty programs, and they seem to be doing well and actually growing. I think there are competitors, and there have been -- this is -- it's an area that I think there's a great need in for that kind of treatment, but we have not seen any real meaningful impact from competition.

    我們其實沒有看到。在這兩個領域確實都有競爭者。我們確實提供一些自閉症服務,但規模不大。我們有數個飲食失調的專科方案,表現似乎不錯,且實際上正在成長。我認為確實有競爭者,而且也一直——這是一個我認為對這類治療有很大需求的領域,但我們尚未看到競爭帶來任何真正有意義的影響。

  • Operator

    Operator

  • Our next question comes from Whit Mayo with UBS.

    我們的下一個問題來自瑞銀(UBS)的 Whit Mayo。

  • Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

    Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

  • Just wanted to go back to the U.K. a bit. I'm struggling a little bit with the guidance. But looking at the fourth quarter, on a constant currency basis, the operating cost per patient day increased about 7%, which is actually sequentially worse. And this trend of continued cost inflation really hasn't improved and just continues to trend in the wrong direction, which I know was partially a function of the retooling efforts. So there's just a lot going on. And I guess, I'm just trying to understand what are you sort of underwriting in your plan for 2024 operating cost per patient day? Or if there's any way that you can provide some context around the last quarter or 2, how much extra expense you're carrying through your run rate right now from all these retooling efforts?

    我想再回到英國的部分談一下。我對指引有點困惑。但如果看第四季,以固定匯率計算,每病人日的營運成本增加了約7%,其實較前一季更差。而這種持續的成本通膨趨勢並沒有改善,反而持續朝錯誤方向發展;我知道其中一部分是重新配置努力的影響。所以有很多事情同時在發生。我想了解的是,你們在計畫中對2024年每病人日營運成本的假設(underwriting)是什麼?或者你們是否能提供一些背景:在最近一到兩季,因為這些重新配置工作,你們目前的營運基準(run rate)中承擔了多少額外費用?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes. Whit, on a cost per patient day basis, we actually see the growth. If you look at it in constant currency, it's less than 5% year-over-year. And that really reflects the service mix and the higher acuity of the patients we're seeing. We are focused on the margin and just making sure that the revenue growth reflects that service mix and that higher acuity. And from that perspective, the margin has been very stable over the last 6 quarters. And as we look at the labor metrics, we've seen stability in both the agency percentage that we're utilizing within the labor as well as just the overall labor cost as a percentage of revenue. So there is an increase in the operating cost, but it does relate to the acuity and service mix that we see.

    是的。Whit,以每病人日成本來看,我們確實看到成長。若以固定匯率來看,年對年其實低於5%。這主要反映了服務組合,以及我們所接收病患的病情嚴重度(acuity)更高。我們聚焦在利潤率,並確保營收成長能反映該服務組合與較高的病情嚴重度。從這個角度來看,過去6個季度的利潤率非常穩定。而在勞動力指標方面,我們看到穩定性:包括我們在勞動力中使用派遣人力(agency)的比例,以及整體勞動成本占營收的比例。因此營運成本確實上升,但這與我們看到的病情嚴重度與服務組合有關。

  • Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

    Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

  • So maybe I didn't understand it. So how are you assuming that trends in 2020? I mean it should moderate. I'm just trying to get a sense of what your assumptions are.

    所以也許是我沒理解。那你們假設2020年的趨勢會如何?我的意思是它應該會趨緩。我只是想掌握你們的假設是什麼。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, it does moderate. The other part of the equation is obviously the volume. And so we have maintained some staff during the retooling, and that allows us to see the volume and the margin benefit as those beds come back online. So that will be reflected in the 2020 cost per patient day numbers, primarily driven by the stability that we see in the labor cost but also the incremental benefit of the volume.

    是的,它確實會趨緩。方程式的另一部分顯然是量(volume)。因此在重新配置期間,我們維持了部分人力配置,這讓我們在那些病床重新上線時,能看到量的提升以及利潤率的效益。所以這會反映在2020年的每病人日成本數字中,主要由我們看到的勞動成本穩定性所驅動,同時也包含量增加帶來的額外效益。

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • And Whit, I'll just add. As we have retooled and we have brought the beds down and we've discharged patients to a lower level of care, there's a core staff that we needed to make sure that the ward is safe. So in some instances, through the year, and actually the third quarter and into the fourth, we were keeping a core group there to make sure that as we ramp down, we had safety on the wards in the U.K.

    Whit,我再補充一下。當我們進行重新配置、降低病床數並將病患出院轉至較低照護層級時,我們需要一個核心人力編制,以確保病房安全。因此在某些情況下,全年期間,實際上在第三季到第四季,我們都保留了一個核心團隊,以確保在英國病房逐步降載時仍能維持安全。

  • Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

    Benjamin Whitman Mayo - Equity Research Analyst of Healthcare Facilities and Managed Care

  • Great. That's helpful. Maybe just 2 quick ones. Of the $20 million of savings that you guys identified from a host of operational initiatives, what do you actually expect to realize in 2020? I know that you'll hit the run rate of $20 million by the fourth quarter, but wanted to know what the incremental realization is. And then for your joint ventures, is there a number to think about for real estate acquisition spend this year? And that's it for me.

    很好。這很有幫助。再兩個快問。你們從一系列營運措施中辨識出的2,000萬美元節省,2020年實際預期能實現多少?我知道你們會在第四季達到2,000萬美元的運行率(run rate),但我想知道增量實現的金額。另外,關於你們的合資企業,今年在不動產收購支出方面,有沒有一個可參考的數字?我就這些。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Well, first, on the operational improvement initiative, we do think that we will gradually build to that $20 million that we achieved by the end of the year. It's somewhat gradual throughout the year and around $10 million is our expectation for what's realized during the year. As it relates to the real estate acquisitions, some of that spending does relate to just when we buy land or when we have other real estate that's acquired relating to an expansion, or a new facility or joint venture project. Going forward, that will continue to be around where it was this year. It typically is around $10 million to $20 million. But we think of that as part of the investments that we're making in the different types of growth.

    首先,關於營運改善計畫,我們確實認為,我們將會逐步累積到年底所達成的2,000萬美元水準。這在全年是相對逐步的,而我們預期在年度期間實現的金額約為1,000萬美元。至於不動產收購,其中部分支出確實與我們購買土地,或因擴建、新設施或合資專案而取得其他不動產的時點有關。展望未來,這部分將會維持在與今年大致相同的水準。通常約在1,000萬至2,000萬美元之間。但我們將其視為我們在不同類型成長上所進行投資的一部分。

  • Operator

    Operator

  • Our next question comes from Matthew Borsch with BMO Capital Markets.

    下一個問題來自BMO Capital Markets的Matthew Borsch。

  • Matthew Richard Borsch - Research Analyst

    Matthew Richard Borsch - Research Analyst

  • I just had a question on the EPS guidance. If I take the high end of your revenue and EBITDA -- adjusted EBITDA ranges and the other guidance that you're giving on D&A and interest expense in the share count, I'm getting to something well above the -- sorry, the range of $220 million to $240 million. If I'm making a stupid mistake, we can take it off-line, but I just wanted to see if there was something obvious that I might be missing. I know the tax rate you're guiding is 17%.

    我想問一下每股盈餘(EPS)指引。如果我採用你們營收與EBITDA—調整後EBITDA區間的高端,以及你們對折舊與攤銷(D&A)、利息費用與股數的其他指引,我算出來的結果會遠高於—抱歉,遠高於2.2億至2.4億美元的區間。如果我犯了很蠢的錯,我們可以私下再談,但我只是想確認是否有什麼明顯的地方是我可能漏掉的。我知道你們指引的稅率是17%。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, Matt, it does depend on the range that you use for those non-operating cost, and we've provided clarity around depreciation and interest. So depending on whether you use the low end throughout all of the numbers or you incorporate some type of high end, yes.

    是的,Matt,這確實取決於你對那些非營運成本所採用的區間,而我們也已就折舊與利息提供了更清楚的說明。因此,視你是全數採用各項數字的低端,或是納入某種高端假設而定,是的。

  • Matthew Richard Borsch - Research Analyst

    Matthew Richard Borsch - Research Analyst

  • Okay, that makes sense. The other question is on the first quarter. It looks like your -- you guided -- I'm getting something sort of flat EBITDA for the first quarter. And I'm just wondering on the revenue line -- sorry, I know revenue was obviously up like 5%. What about the calendar impact? How are you estimating that? Isn't that a benefit, both with respect to the leap day, obviously, but there's also a little bit of other year-over-year benefit there?

    好的,這就說得通了。另一個問題是關於第一季。看起來你們—你們的指引—我算出第一季的EBITDA大致持平。我想問的是營收那一行—抱歉,我知道營收顯然成長了大約5%。那行事曆因素的影響呢?你們是如何估算的?那不是一個利多嗎?不僅是閏日的影響,顯然還有一些其他的年對年利多在裡面?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, we do see a benefit from having 1 extra day compared to the first quarter of 2019. We estimate that somewhere in the range of $1 million to $2 million. But that is a year-over-year benefit that we expect.

    是的,與2019年第一季相比,多出1天我們確實看到有利影響。我們估計大約在100萬到200萬美元之間。但這確實是我們預期的年對年利多。

  • Matthew Richard Borsch - Research Analyst

    Matthew Richard Borsch - Research Analyst

  • Okay. And how are you thinking about the stranded -- if -- well, are there any stranded costs as you see it, or at least lost operating leverage that you would expect to have for some period of time after the U.K. sale?

    好的。那你們如何看待所謂的閒置—如果—嗯,你們認為是否有任何閒置成本(stranded costs),或至少在英國出售之後,有一段時間會出現營運槓桿流失?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • No, there's really not. I mean, the U.S. corporate office costs that we mentioned a minute ago relate specifically to our U.S. facilities. And there are a few million of costs that we have within that number just that relate to the cost of us being a multinational company if you think about higher professional fees relating to tax requirements and things like that. So there will be a wind down of a few million of additional costs that we carry. But we don't think about there being any stranded cost, just given the self-sufficiency of each of those 2 segments.

    沒有,基本上沒有。我的意思是,我們剛才提到的美國總部辦公室成本,是專門與我們的美國設施相關。而在那個數字裡,我們有幾百萬美元的成本,純粹是與我們作為跨國公司所需承擔的成本有關,例如因稅務要求等而產生較高的專業服務費用之類。因此,我們所承擔的額外成本中,會有幾百萬美元會逐步收斂(wind down)。但考量到這兩個事業部門各自的自給自足性,我們不認為會有任何閒置成本。

  • Matthew Richard Borsch - Research Analyst

    Matthew Richard Borsch - Research Analyst

  • Let me just -- one last question on that, which is, do you think that we externally have the data elements to really estimate what the run -- earnings run rate is going to look like post the sale of U.K., I mean, absent the impacts maybe of the capital reallocation from that sale?

    讓我再—就這點最後問一個問題:你認為我們外部是否具備足夠的資料要素,來真正估算英國出售後的—也就是,出售後的獲利常態化水準(earnings run rate)會長什麼樣子?我的意思是,先不考慮可能來自該出售之資本再配置的影響。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, Matt, we do. And part of our intent in providing the U.K. depreciation number and other metrics is just to give you all the information that we think you need.

    是的,Matt,我們認為有。而我們提供英國折舊數字與其他指標的部分用意,就是為了把我們認為你們所需要的資訊都提供給你們。

  • Operator

    Operator

  • Our next question comes from John Ransom with Raymond James.

    下一個問題來自Raymond James的John Ransom。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • In the Wayback Machine, when you bought CRC from Bain, you had about $475 million of revenue, 600 empty beds. And I don't think you guys disclosed how big the methadone business was. But could you just approximately size that business today? And I'm particularly interested in how much the methadone business has grown in the last 6 years.

    回到很久以前,當你們從Bain手上買下CRC時,你們大約有4.75億美元的營收、600張空床。而我不認為你們當時有揭露美沙酮(methadone)業務的規模有多大。但你能否大致說明一下今天該業務的規模?我特別想了解美沙酮業務在過去6年成長了多少。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • We have 127 clinics. We're now in 32 different states. We have seen strong performance in that business, improvement in the coverage that we have and really a diversified payer mix within that business. So we've seen strong revenue growth in line with what we've reported on an organic basis for our U.S. facilities. It's part of that number. So hopefully, that helps you size where the business is today. We don't separately report revenue relating to that segment because it's just -- it's one component of our U.S. operations.

    我們有127家診所。我們目前遍及32個州。我們看到該業務表現強勁,覆蓋範圍有所改善,而且在該業務中有相當多元的付款方組合(payer mix)。因此,我們看到強勁的營收成長,與我們對美國設施所報告的有機成長趨勢一致。它是那個數字的一部分。希望這能幫助你衡量目前該業務的規模。我們不會單獨揭露該服務線的營收,因為它只是—它只是我們美國營運中的一個組成部分。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • Do you remember how many you had when you bought it roughly versus the 127?

    你還記得你們收購時大概有多少家嗎?相較於現在的127家。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • John, I don't. I think it was somewhere around 75 clinics. We've done 4 or so tuck-in acquisitions within that service line.

    John,我不記得了。我想大概在75家診所左右。我們在該服務線內做了大約4筆補強型(tuck-in)收購。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • Okay. And do you remember kind of approximately -- of the $475 million at the time, what percent of that was -- is it fair to say that was maybe 25% of the mix at the time? Is that crazy?

    好的。那你還記得當時4.75億美元之中,大概有多少比例是—可以說當時大概占組合的25%嗎?這樣說會不會太離譜?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • I don't remember what that represented of the CRC business. But where we are today, that segment, that service line is around 15%, 17% of our U.S. revenue. But I don't recall what piece of previous acquisitions that was.

    我不記得那在CRC業務中占比是多少。但以我們今天的情況來看,該部門、該服務線約占我們美國營收的15%到17%。但我不記得在先前收購時那部分占多少。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • And then just last one for me is, of the beds you've added and plan to add in 2020, so let's kind of take '18, '19, '20, approximately what percent of those are de novos, freestanding, stand-alones versus adding beds to existing facilities?

    那我最後一個問題是,在你們已新增且計畫於2020年新增的床位中,我們把'18、'19、'20合在一起看,大概有多少比例是新設(de novo)、獨立設施、單點(stand-alone),相較於在既有設施中增加床位?

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • John, our de novos are 300 of the 600, and the remaining are bed additions that we will be making to our existing facilities. So it's about half and half.

    John,我們的新設(de novo)是600張中的300張,其餘則是我們將在既有設施中新增的床位。所以大約各占一半。

  • Operator

    Operator

  • We'll take our next question from Gary Taylor with JPMorgan.

    我們下一個問題來自JPMorgan的Gary Taylor。

  • Gary Paul Taylor - Analyst

    Gary Paul Taylor - Analyst

  • Most of my questions are answered. I just wanted to understand just a little bit of the U.S. trajectory year-over-year and sequentially. So it looks like if we adjust for the AR charge in the fourth quarter of 2018, did see improvement sequentially in the U.S. same-store margins. They were down about 140 in the third, down about 90 adjusted in the fourth. So are you -- based on your comments, I guess, implying that you do think same-store margin U.S. are down in the first half, and then they'll be up in the second half? Sounds like that's what's sort of underlying the guide.

    我大部分的問題都已經得到解答了。我只是想更了解一下美國業務年對年以及季對季的走勢。所以看起來如果我們調整2018年第四季的應收帳款(AR)費用(charge),美國同店毛利率(same-store margins)季對季確實有所改善。第三季大約下滑140個基點,第四季在調整後大約下滑90個基點。所以—根據你們的評論,我猜是在暗示你們確實認為美國同店毛利率在上半年會下滑,而在下半年會回升?聽起來這就是指引背後的主要假設。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, Gary, we do, and hopefully, we provided enough explanation around some of the factors driving that. There are a few other factors that we do think contributes to that. I'll give you just another example that will hopefully just help you understand the guidance throughout the year. We did make a change in the timing of our merit increases for our U.S. facilities. So in 2020, we are transitioning that merit increase to happen rather than at each employee's annual anniversary date to once a year, either in January or April, for all facilities. This is an improvement, not only in just the -- in the process, the employee evaluation process and performance review process, but also just the visibility, the control that we have as we think about facility level cost. As part of that, there was a shift just that we will be going through, on a onetime basis, that affects the year-over-year comparison '20 versus 2019. It does shift some cost to the first half of the year, but will result in more stable cost throughout the year going into the second half of the year. So that, along with some of the other factors that we mentioned around the specific facilities improving, bed additions coming online, the operational improvements, that's part of our margin expectation improving throughout the year.

    是的,Gary,我們確實有,而且希望我們已就推動該情況的一些因素提供了足夠的說明。我們認為還有幾個其他因素也對此有所貢獻。我再舉一個例子,希望能幫助你理解我們全年指引的脈絡。我們確實調整了美國各設施績效調薪(merit increases)的時點。因此在2020年,我們正把原本在每位員工年度到職週年日進行的績效調薪,改為所有設施每年一次,於1月或4月進行。這是一項改善,不僅在流程上——包括員工評估流程與績效考核流程——也提升了我們在思考設施層級成本時的可視性與控管能力。作為其中一部分,會有一次性的時點移轉,影響2020年相較2019年的年對年比較。這確實會把部分成本移到上半年,但在進入下半年後,將使全年成本走勢更為穩定。因此,這一點再加上我們提到的其他因素——特定設施的改善、增床陸續上線、營運改善——共同構成我們預期利潤率在全年逐步改善的一部分。

  • Gary Paul Taylor - Analyst

    Gary Paul Taylor - Analyst

  • And that sounds like the segment -- my follow-up was just, it looks like consolidated margins, down 40 this quarter. Your first quarter guidance was for those margins to be down about 100 basis points year-over-year. So it sounds like there's some of the corporate overhead stuff you talked about stepping up. Also, this change on the merit comp probably, I guess, would be 2 of the biggest factors on just that sequential guide.

    了解,聽起來是分部層面——我追問的是,看起來本季合併利潤率下滑了40個基點。你們對第一季的指引是利潤率年對年下滑約100個基點。所以聽起來,你提到的公司層級管理費用(corporate overhead)上升是其中一部分。另外,這次績效薪酬調整的變更,我想大概也是兩個最大因素之一,影響這個逐季指引的變化。

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • Yes, that's right, Gary.

    是的,沒錯,Gary。

  • Operator

    Operator

  • Our next question comes from Ryan Daniels with William Blair.

    下一個問題來自 William Blair 的 Ryan Daniels。

  • Nicholas Charles Spiekhout - Associate

    Nicholas Charles Spiekhout - Associate

  • Nick Spiekhout in for Ryan. I guess, I know we talked about this in the past, and you haven't seen anything, but I'm just wondering what you guys are seeing on the labor front in the U.S. I know a competitor noted they're having some trouble filling some vacancies, and I think they quoted that their annual wage increases jumped about 1% this year. So just a little bit of update there, if you can.

    我是代 Ryan 提問的 Nick Spiekhout。我想,我知道我們過去談過這個,而你們也尚未看到什麼變化,但我想請問你們在美國勞動力方面看到的情況如何?我知道有競爭對手提到他們在填補部分職缺上遇到一些困難,而且我記得他們說今年年度薪資調幅大約多了1%。所以如果可以的話,想請你們就這方面提供一點最新狀況。

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • This is Debbie. We haven't really seen labor pressures really differ from 2019 or project them to. I think part of -- looking at others in the industry, we have our service lines that I believe factor into some of the labor pressures, particularly around RNs. We do have the specialty area and CTC, which are not as dependent on RNs. They use other professionals. And the other, I think, factor, which I think is very positive is we have had a very focused process on recruiting and retention. And I think that while we make changes in markets when we think we might be at a point where we might limit census, which we have not done, and we see capacity issues developing because of staffing, we have been proactive in making sure that we're putting in wage adjustments as necessary. It's very variable by market. And I think, again, comparing to others in the industry, we're not in all of the same markets. So we have markets where we do have pressures, but then we have others where we're keeping up with the competition through our wages.

    我是 Debbie。我們並沒有看到勞動力壓力相較2019年有明顯不同,也沒有預期會有。我想其中一部分——看其他同業——我們的服務線(service lines)我認為會影響到某些勞動力壓力,特別是在註冊護理師(RNs)方面。我們確實有專科領域以及 CTC,這些對 RNs 的依賴度沒那麼高。它們使用其他專業人員。另外一個我認為非常正面的因素是,我們在招募與留任方面一直有非常聚焦的流程。我認為,當我們判斷某些市場可能接近需要限制收治量(census)的點——我們目前並未這麼做——且因人力配置而出現產能問題時,我們一直很主動地在必要時進行薪資調整。這在不同市場之間差異很大。而且我想,再次與同業相比,我們並不在所有相同的市場。因此,我們有些市場確實有壓力,但也有其他市場,我們透過薪資水準與競爭對手保持同步。

  • Nicholas Charles Spiekhout - Associate

    Nicholas Charles Spiekhout - Associate

  • Great. And I guess, just shifting to the U.K. retooling. What's the progression of that for 2020? Is that weighted in the back half or the front half or pretty even about for those beds coming back online?

    很好。那我想把話題轉到英國的整備(retooling)。2020年這方面的進度會是如何?是偏向下半年、上半年,還是這些床位重新上線的節奏大致平均?

  • David M. Duckworth - CFO

    David M. Duckworth - CFO

  • It's really evenly throughout the year. We do have some of the projects that tend to be larger than others. They typically range between 10 and 30 beds each. And we have the first one, is ready to open in March and it has a block contract for the reopening. And so it's starting in March, and it's somewhat evenly throughout the year.

    基本上全年都相當平均。我們確實有一些專案規模會比其他更大。通常每個專案大約介於10到30張床。第一個專案在3月就準備開放,且在重新開放時有一份區塊合約(block contract)。因此會從3月開始,並且全年節奏大致平均。

  • Operator

    Operator

  • And that does conclude the question-and-answer session. I'd like to turn the call back over to Debbie Osteen for any additional or closing remarks.

    問答環節到此結束。我想把電話交回給 Debbie Osteen,請她做任何補充或結語。

  • Debra K. Osteen - CEO & Director

    Debra K. Osteen - CEO & Director

  • I just want to say thanks for being with us today and for your interest in Acadia Healthcare. I'd like to conclude by thanking all of our employees and our clinicians. Every day, they show real dedication and focus. They want to provide the highest quality care to our patients and our families, and I appreciate their efforts, and I just want to thank them.

    我只想說,感謝各位今天與會,也感謝各位對 Acadia Healthcare 的關注。最後我想感謝我們所有員工與臨床人員。他們每天都展現出真正的投入與專注。他們希望為我們的病患與家屬提供最高品質的照護,我很感謝他們的付出,也想向他們致謝。

  • I'll also say that if you have additional questions today, please do not hesitate to contact us directly. And have a good day.

    我也想補充,如果各位今天還有其他問題,請隨時直接與我們聯繫。祝各位有美好的一天。

  • Operator

    Operator

  • And that concludes today's presentation. Thank you for your participation, and you may now disconnect.

    以上為今天的簡報內容。感謝各位的參與,現在可以掛線。